Table 3.
Antiviral activity against drug-resistant HIV-1 strains in MT-4.
| Laboratory virus strain | Genotype | Mean EC50 (μM) ± SD |
||
|---|---|---|---|---|
| Positive control (nM) | MDH-1-38 | NS1040 | ||
| Enfuviritide-resistant | Env V38A/N126K | AZT 1.5 ± 0.5 | 7.09 ± 0.03 | 5.48 ± 0.01 |
| Indinavir-resistant, Ritonavir-resistant | PR V82F/I84V | AZT 2.0 ± 0 | 4.10 ± 0.47 | 3.52 ± 1.70 |
| Indinavir-resistant, Ritonavir-resistant | PR V82A | AZT 3.5 ± 0.5 | 10.3 ± 5.34 | 6.73 ± 1.06 |
| Indinavir-resistant, Ritonavir-resistant | PR I84V | AZT 2.5 ± 1.5 | 2.54 ± 0.93 | 3.33 ± 0.44 |
| Saquinavir-resistant | PR G48V/L90M | AZT 3.5 ± 2.5 | 1.0 ± 0.34 | 1.10 ± 0.32 |
| Atazanavir-resistant | PR I50L | AZT 1.5 ± 0.5 | 0.82 ± 0.37 | 1.27 ± 0.19 |
| NNRTI-resistant | RT K103N | AZT 0.9 ± 0.1 | 3.97 ± 1.31 | 5.02 ± 0.14 |
| NNRTI-resistant | RT L100I | AZT 0.65 ± 0.5 | 1.22 ± 0.01 | 1.61 ± 0.41 |
| NNRTI-resistant | RT Y181C | AZT 1.0 ± 0 | 3.99 ± 1.59 | 4.52 ± 1.07 |
| NNRTI-resistant | RT V106A | AZT 2.0 ± 1.0 | 2.74 ± 2.17 | 4.07 ± 0.78 |
| Lamivudine-resistant | RT M184V | AZT 0.55 ± 0.05 | 2.70 ± 1.52 | 3.50 ± 1.1 |
| NNRTI-resistant | RT V108I | AZT 1.5 ± 0.5 | 3.84 ± 1.60 | 4.70 ± 0.17 |
| AZT-resistant | RT 4xAZT (D67N/K70R/T215Y/K219Q) | NVP 35 ± 15 | 3.31 ± 2.20 | 4.24 ± 0.91 |
| AZT- and NNRTI-resistant | RT 4xAZT/Y181C | AZT 7.0 ± 4.2 | 4.87 ± 0.22 | 5.24 ± 0.18 |
| AZT- and NNRTI-resistant | RT 4xAZT/L100I | AZT 4.0 ± 0.71 | 3.59 ± 1.25 | 3.54 ± 2.02 |
| Didanosine-resistant | RT L74V | AZT 2.0 ± 0 | 3.93 ± 2.33 | 4.59 ± 0.61 |
| NNRTI-resistant | RT V179D | AZT 1.0 ± 0.3 | 3.57 ± 1.81 | 5.01 ± 0.31 |
| NNRTI-resistant | RT Y188C | AZT 1.5 ± 0.5 | 3.37 ± 2.15 | 4.72 ± 0.55 |
| Tenofovir-resistant | RT K65R | RTV 0.06 ± 0.02 | 4.29 ± 0.64 | 5.21 ± 0.08 |
| NNRTI-resistant | RT K103N/Y181C | AZT 2.0 ± 0 | 8.03 ± 1.45 | 5.19 ± 0.06 |
| Raltegravir-resistant | IN Q148H/G140S | AZT 2.0 ± 0 | 3.39 ± 2.15 | 4.16 ± 0.26 |